Hopeful Breakthrough: Tata Institute Develops Tablet to Fight Cancer Recurrence- written by Aishee Biswas (Managing Editor, Bisjhintus News)

Researchers at the Tata Institute of Fundamental Research (TIFR) in Mumbai, India, have developed a promising tablet, named "R+Cu," that holds the potential to prevent cancer recurrence and reduce the harsh side effects of cancer treatment.

 

The tablet, which combines resveratrol and copper, works by targeting cell-free chromatin particles (cfChPs) released by dying cancer cells. These particles can, in some cases, transform healthy cells into cancerous ones. The R+Cu formula generates oxygen radicals that destroy these cfChPs, hindering this transformation and potentially preventing cancer reoccurrence.

 

Initial studies in animal models have shown a 30% effectiveness in preventing cancer recurrence, along with a significant reduction in side effects associated with chemotherapy and radiation therapy by nearly 50%. While further clinical trials are needed to confirm its efficacy and safety in humans, these initial findings offer a glimmer of hope for cancer patients struggling with treatment and the fear of recurrence.

 

Dr. Rajendra Badve, a senior cancer surgeon at the Tata Memorial Hospital, stated that the tablet is currently awaiting approval from the Food Safety and Standards Authority of India (FSSAI). Once approved, it is expected to be available at a highly affordable price of around Rs 100, making it accessible to a wider population.

 

This development marks a significant step forward in the fight against cancer, offering a potentially cost-effective and well-tolerated intervention to improve patient outcomes and quality of life. However, it is crucial to remember that this is a new discovery, and further research is necessary to determine its long-term efficacy and safety profile.